% | $
Quotes you view appear here for quick access.

Incyte Corporation Message Board

  • viseslinger viseslinger Jan 10, 2013 8:53 AM Flag

    Motley Fool: Maintains a CAPScall of outperform on Incyte and fully expect the drugmaker to charge higher from here.

    When Incyte wasn't raving about Jakafi for MF -- which was few and far between -- it did note that its late-stage trial utilizing Jakafi for the treatment of polycythemia vera should deliver results in the latter half of this year with an expectation of a new drug application filing by the first-half of 2014 assuming all endpoints are met. It also has an ongoing mid-stage trial for Jakafi for the treatment of pancreatic cancer.

93.20+4.13(+4.64%)Sep 28 4:00 PMEDT